poisar

Stocks · News reference

8-K filing — Vaxart, Inc. (VXRT)

Aug 25, 2026, 8:12 PMSEC EDGAR

Filed: 2026-08-25 AccNo: 0001437749-26-028916 Size: 148 KB Item 8.01: Other Events

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VXRT
Source
edgar
Observed
Aug 25, 2026, 8:12 PM
Checked
Aug 25, 2026, 8:12 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Jul 1, 2026, 8:00 PMNa

    Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements

    Vaxart resolved a proxy contest by entering a cooperation agreement with a stockholder group. The company will appoint a mutually agreed independent director within 90 days and form new board committees focused on stockholder engagement and clinical/regulatory affairs. The stockholder group withdrew its director nominations in exchange for enhanced corporate governance measures.

    Read original at globenewswire-inc
    VXRT
  2. Jun 26, 2026, 12:00 PMNa

    Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

    Vaxart is urging shareholders to vote for all six of its director nominees on the WHITE proxy card ahead of its July 16, 2026 Annual Meeting. The company highlights strategic progress on its oral vaccine pipeline, including Phase 2b COVID-19 trials and partnerships with Dynavax, while defending its board against dissident nominees it claims lack relevant biotech expertise. Vaxart has made multiple settlement offers to resolve the proxy contest.

    Read original at globenewswire-inc
    VXRT